Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Active Not Recruiting1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT01552434Phase 1Active Not Recruiting

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

NCT06356272Recruiting

Oropharynx (OPX) Biomarker Trial

Showing all 2 trials

Research Network

Activity Timeline